Joseph A. Kozlowski
Research Subjects
Joseph A. Kozlowski has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Anilkumar G. Nair
Department of Medicinal Chemistry, Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA
2 shared publicationsBin Hu
WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China
2 shared publicationsBin Zhong
WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China
2 shared publications- Ernest Asante-Appiah
Merck & Co., Inc., Rahway, NJ, USA
2 shared publications Gordon Crosby
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-0539, USA
2 shared publicationsGuowei Zhou
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-0539, USA
2 shared publications
Latest Publications
- 1 August 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (15) , 3793-3799
Discovery of potent macrocyclic HCV NS5A inhibitors
- 1 August 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (15) , 3793-3799
Discovery of potent macrocyclic HCV NS5A inhibitors
- 1 July 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (13) , 3158-3162
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity
- 1 July 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (13) , 3158-3162
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity
- Open Access
- 11 November 2009
- Published by Springer Nature in Journal of Inflammation
- Vol. 6 (1) , 32
CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis
Background: CCR2 plays a key role in regulating monocyte trafficking to sites of inflammation and therefore has been the focus of much interest as a target for inflammatory disease. Methods: Here we examined the effects of CCR2 blockade with a potent small molecule antagonist to determine the pharmacodynamic consequences on the peripheral blood monocyte compartment in the context of acute and chronic inflammatory processes. Results: We demonstrate that CCR2 antagonism in vivo led to a rapid decrease in the number of circulating Ly6Chi monocytes and that this decrease was largely due to the CXCR4-dependent sequestration of these cells in the bone marrow, providing pharmacological evidence for a mechanism by which monocyte dynamics are regulated in vivo. CCR2 antagonism led to an accumulation of circulating CCL2 and CCL7 levels in the blood, indicating a role for CCR2 in regulating the levels of its ligands under homeostatic conditions. Finally, we show that the pharmacodynamic changes due to CCR2 antagonism were apparent after chronic dosing in mouse experimental autoimmune encephalomyelitis, a model in which CCR2 blockade demonstrated a dramatic reduction in disease severity, manifest in a reduced accumulation of monocytes and other cells in the CNS. Conclusion: CCR2 antagonism in vivo has tractable pharmacodynamic effects that can be used to align target engagement with biologic effects on disease activity.
- 11 November 2009
- Published by Springer Nature in Journal of Inflammation
- Vol. 6 (1) , 32
Open AccessCCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis
Background: CCR2 plays a key role in regulating monocyte trafficking to sites of inflammation and therefore has been the focus of much interest as a target for inflammatory disease. Methods: Here we examined the effects of CCR2 blockade with a potent small molecule antagonist to determine the pharmacodynamic consequences on the peripheral blood monocyte compartment in the context of acute and chronic inflammatory processes. Results: We demonstrate that CCR2 antagonism in vivo led to a rapid decrease in the number of circulating Ly6Chi monocytes and that this decrease was largely due to the CXCR4-dependent sequestration of these cells in the bone marrow, providing pharmacological evidence for a mechanism by which monocyte dynamics are regulated in vivo. CCR2 antagonism led to an accumulation of circulating CCL2 and CCL7 levels in the blood, indicating a role for CCR2 in regulating the levels of its ligands under homeostatic conditions. Finally, we show that the pharmacodynamic changes due to CCR2 antagonism were apparent after chronic dosing in mouse experimental autoimmune encephalomyelitis, a model in which CCR2 blockade demonstrated a dramatic reduction in disease severity, manifest in a reduced accumulation of monocytes and other cells in the CNS. Conclusion: CCR2 antagonism in vivo has tractable pharmacodynamic effects that can be used to align target engagement with biologic effects on disease activity.
- 1 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (5) , 791-794
Substituted 2-(R)-Methyl piperazines as muscarinic M2 selective ligands
- 1 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (5) , 791-794
Substituted 2-(R)-Methyl piperazines as muscarinic M2 selective ligands
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2255-2257
Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2255-2257
Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor